Skip to main content
Toggle navigation
Login
Search
Home
Tweets by IDWeek 2023
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
On Demand
Back
Favorite
Facebook
Tweet
Print
Jennifer Smart, PhD
Sr. Microbiologist, Development
Basilea Pharmaceutica International Ltd, Switzerland
Poster(s):
(2162)
In Vitro
Antimicrobial Activity of Ceftobiprole against
Streptococcus pneumoniae
Isolates from the United States (2016–2020)
Saturday, October 14, 2023
12:15 PM – 1:30 PM
US ET
(2173) Activity of Ceftobiprole Against
Enterococcus faecalis
Clinical Isolates From the United States (2016–2020), Including Those From Difficult-to-Treat Infections
Saturday, October 14, 2023
12:15 PM – 1:30 PM
US ET
(2530) Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dose Selection for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-Acquired Bacterial Pneumonia (CABP)
Saturday, October 14, 2023
12:15 PM – 1:30 PM
US ET
(2531) Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dosing Regimens for Patients with
Staphylococcus aureus
Bacteremia (SAB)
Saturday, October 14, 2023
12:15 PM – 1:30 PM
US ET
(2532) Pharmacokinetic-Pharmacodynamic Analyses for Ceftobiprole Efficacy Based on Phase 3 Data from Patients with
Staphylococcus aureus
Bacteremia
Saturday, October 14, 2023
12:15 PM – 1:30 PM
US ET
(2561) Population Pharmacokinetic Analyses for Ceftobiprole Using Data from Phase 1 and 3 Studies
Saturday, October 14, 2023
12:15 PM – 1:30 PM
US ET
(2785) Characterization of Methicillin-resistant
Staphylococcus aureus
Bloodstream Isolates Recovered from Patients Enrolled in a Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole for Treatment of Bacteremia, Including Infective Endocarditis
Saturday, October 14, 2023
12:15 PM – 1:30 PM
US ET